Patents by Inventor Andreas Loew

Andreas Loew has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20250011459
    Abstract: Multispecific molecules that include an anti-G6B antibody or binding fragment thereof, an anti-CD34 antibody or binding fragment thereof; and one, two or all of: an immune cell engager (e.g., selected from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, and a macrophage cell engager); a cytokine molecule; a modulator of a cytokine molecule; a stromal modifying moiety; or any combination thereof are disclosed. Additionally disclosed are nucleic acids encoding the same, and methods of treating conditions or diseases using the aforementioned molecules.
    Type: Application
    Filed: July 22, 2024
    Publication date: January 9, 2025
    Inventors: Andreas Loew, Madan Katragadda, Roya Servattalab
  • Publication number: 20250011461
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
    Type: Application
    Filed: August 2, 2024
    Publication date: January 9, 2025
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Huijuan Song, Qilong Wu
  • Patent number: 12152073
    Abstract: Multifunctional molecules that include i) an antigen binding domain that binds to a calreticulin mutant protein; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule or a modulator of a cytokine molecule; and/or (iv) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: November 26, 2024
    Assignee: MARENGO THERAPEUTICS, INC.
    Inventors: Andreas Loew, Ilaria Lamberto, John Leonard Herrmann, Brian Edward Vash
  • Patent number: 12134654
    Abstract: Multispecific molecules targeting tumor associated macrophages (TAMs) or myeloid derived suppressor cells (MDSCs) and methods of using the same, are disclosed.
    Type: Grant
    Filed: April 19, 2018
    Date of Patent: November 5, 2024
    Assignee: MARENGO THERAPEUTICS, INC.
    Inventors: Andreas Loew, Brian Edward Vash, Stephanie J. Maiocco
  • Publication number: 20240317850
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Application
    Filed: April 2, 2024
    Publication date: September 26, 2024
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Michael C. Milone, Huijuan Song, Enxiu Wang, Qilong Wu
  • Publication number: 20240301060
    Abstract: The disclosure provides antibody molecules that bind to TCR V? regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
    Type: Application
    Filed: February 2, 2024
    Publication date: September 12, 2024
    Inventors: Seng-Lai Tan, Brian Edward Vash, Jonathan Hsu, Dilini Charmain Gunasekera, Sangeetha Sagar Palakurthi, Andreas Loew
  • Publication number: 20240294662
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
    Type: Application
    Filed: April 26, 2024
    Publication date: September 5, 2024
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Huijuan Song, Qilong Wu
  • Publication number: 20240238396
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
    Type: Application
    Filed: November 9, 2023
    Publication date: July 18, 2024
    Inventors: Jennifer Brogdon, Laura Alexandra Johnson, Carl H. June, Andreas Loew, Marcela Maus, John Scholler, Hideho Okada
  • Patent number: 11999794
    Abstract: Provided are compositions and methods for treating diseases associated with expression of mesothelin. Also provided are a chimeric antigen receptor (CAR) specific to mesothelin, vectors encoding the same, and recombinant T cells comprising the mesothelin CAR. Further provided are methods of administering a genetically modified T cell expressing a CAR that comprises a mesothelin binding domain.
    Type: Grant
    Filed: January 23, 2020
    Date of Patent: June 4, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Huijuan Song, Qilong Wu
  • Patent number: 11981731
    Abstract: The present invention provides compositions and methods for regulating the specificity and activity of immune effector cells for use in immunotherapy. In one embodiment, the invention provides a type of chimeric antigen receptor (CAR) wherein the CAR is termed a “NKR-CAR” which is a CAR design comprising a component of a receptor naturally found on natural killer (NK) cells. In one embodiment, the NK receptor includes but is not limited to a naturally occurring activating and inhibitory receptor of NK cells known as a killer cell immunoglobulin-like receptor (KIR).
    Type: Grant
    Filed: January 15, 2020
    Date of Patent: May 14, 2024
    Assignees: The Trustees of the University of Pennsylvania, Novartis AG
    Inventors: Gregory Beatty, Boris Engels, Neeraja Idamakanti, Carl H. June, Andreas Loew, Michael C. Milone, Huijuan Song, Enxiu Wang, Qilong Wu
  • Patent number: 11965025
    Abstract: The disclosure provides antibody molecules that bind to TCR V? regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
    Type: Grant
    Filed: August 18, 2022
    Date of Patent: April 23, 2024
    Assignee: Marengo Therapeutics, Inc.
    Inventors: Seng-Lai Tan, Brian Edward Vash, Jonathan Hsu, Dilini Charmain Gunasekera, Sangeetha Sagar Palakurthi, Andreas Loew
  • Publication number: 20240083968
    Abstract: The present invention features the use of chimeric CD3 proteins to modulate T cell Receptor (TCR) signaling. Specifically, the invention is based, in part, on the discovery that chimeric CD3 proteins (e.g., CD3delta, CD3gamma, and CD3 epsilon) having all or most of their extracellular domain fused to an antigen binding domain can activate the TCR in the presence of a cognate antigen. The invention is further based on the observation that the above chimeric proteins can be potentiated through the inclusion of a co-stimulatory domain in the intracellular portion of the chimeric molecule. Thus, the preferred elements of the engineered signaling complexes of the invention include an antigen binding domain, an extracellular domain derived from one of the above CD3 proteins, and an intracellular co-stimulatory domain.
    Type: Application
    Filed: April 21, 2023
    Publication date: March 14, 2024
    Inventors: Andreas Loew, Brian Granda, Melissa Ramones
  • Publication number: 20240076377
    Abstract: The disclosure provides antibody molecules that bind to TCR V? regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
    Type: Application
    Filed: September 22, 2023
    Publication date: March 7, 2024
    Inventors: Seng-Lai Tan, Brian Edward Vash, Jonathan Hsu, Dilini Charmain Gunasekera, Sangeetha Sagar Palakurthi, Andreas Loew
  • Publication number: 20240026330
    Abstract: Provided herein are fusion protein comprising: an effector domain comprising a catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof; and a targeting domain comprising a moiety that specifically binds a mitochondrial protein. Also provided herein are methods of using the fusion proteins to treat a disease, including genetic diseases.
    Type: Application
    Filed: November 5, 2021
    Publication date: January 25, 2024
    Inventors: Andreas LOEW, Samuel W. HALL
  • Publication number: 20240025984
    Abstract: Provided herein are fusion protein comprising: an effector domain comprising a catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof; and a targeting domain comprising a moiety that specifically binds a cytosolic protein. Also provided herein are methods of using the fusion proteins to treat a disease, including genetic diseases.
    Type: Application
    Filed: November 5, 2021
    Publication date: January 25, 2024
    Inventors: Andreas LOEW, Samuel W. HALL
  • Publication number: 20240026329
    Abstract: Provided herein are fusion protein comprising: an effector domain comprising a catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof; and a targeting domain comprising a moiety that specifically binds a nuclear protein. Also provided herein are methods of using the fusion proteins to treat a disease, including genetic diseases.
    Type: Application
    Filed: November 5, 2021
    Publication date: January 25, 2024
    Inventors: Andreas LOEW, Samuel W. HALL
  • Patent number: 11865167
    Abstract: The invention provides compositions and methods for treating diseases associated with expression of EGFRvIII. The invention also relates to chimeric antigen receptor (CAR) specific to EGFRvIII, vectors encoding the same, and recombinant T cells comprising the anti-EGFRvIII CAR. The invention also includes methods of administering a genetically modified T cell expressing a CAR that comprises an anti-EGFRvIII binding domain.
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: January 9, 2024
    Assignees: Novartis AG, The Trustees of the University of Pennsylvania, University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Jennifer Brogdon, Laura Alexandra Johnson, Carl H. June, Andreas Loew, Marcela Maus, John Scholler, Hideho Okada
  • Publication number: 20240002473
    Abstract: Provided herein are fusion protein comprising: an effector domain comprising a catalytic domain of a deubiquitinase, or a functional fragment or functional variant thereof; and a targeting domain comprising a moiety that specifically binds a membrane protein. Also provided herein are methods of using the fusion proteins to treat a disease, including genetic diseases.
    Type: Application
    Filed: November 5, 2021
    Publication date: January 4, 2024
    Inventors: Andreas LOEW, Samuel W. HALL
  • Publication number: 20240002543
    Abstract: Multifunctional molecules that include i) an antigen binding domain that binds to a calreticulin protein; and one, two or all of: (ii) an immune cell engager (e.g., chosen from an NK cell engager, a T cell engager, a B cell engager, a dendritic cell engager, or a macrophage cell engager); (iii) a cytokine molecule; and/or (iv) a stromal modifying moiety are disclosed. Additionally disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
    Type: Application
    Filed: February 24, 2023
    Publication date: January 4, 2024
    Inventors: Andreas Loew, Madan Katragadda, Saeyoung Park, Roya Servattalab
  • Patent number: 11845797
    Abstract: The disclosure provides antibody molecules that bind to TCR V? regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
    Type: Grant
    Filed: July 3, 2019
    Date of Patent: December 19, 2023
    Assignee: Marengo Therapeutics, Inc.
    Inventors: Seng-Lai Tan, Brian Edward Vash, Jonathan Hsu, Dilini Charmain Gunasekera, Sangeetha Sagar Palakurthi, Andreas Loew